Table 1

Schedule of study assessments

Visit number	V1	P1	V2	P2	V3	P3	V4	P4	P5	V5	P6	P7	V6	P8	P9	V7	D1
Assessment description	Screening and baseline	Follow-up														End of study	End of down-titration
Time since randomisation W=weeks, M=months	0 W	2 W	4 W	8 W	12 W	16 W	6 M	8 M	10 M	12 M	14 M	16 M	18 M	20 M	22 M	24 M	24 M+1–3 W
Visit type	Clinic	Phone	Clinic	Phone	Clinic	Phone	Clinic	Phone	Phone	Clinic	Phone	Phone	Clinic	Phone	Phone	Clinic	Clinic
Visit window	±0 W	±1 W	±2 W	±1 W	±2 W	−2 W+4 W	±4 W	±1 W	±1 W	±4 W	±1 W	±1 W	±4 W	±1 W	±1 W	±4 W	±1 W
Informed consent/eligibility	X
Reasons for non-participation	X
Demographics, medical, clinical and smoking history	X
Physical examination and anthropometrics	X															X*
Randomisation	X
Vital signs and vital status BP, HR	X†		X		X		X			X			X			X	X
Spirometry	X‡		X		X		X			X			X			X	X
ECG	X§		X		X					X						X	X
CAT, SGRQ and EQ-5D-5L¶	X						X			X			X			X
Adverse events	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant medications	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
6MWT**	X									X
Medication dosage review			X	X	X
Participant diary review			X		X		X			X			X			X
Treatment adherence††		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

* Weight only for anthropometrics at V7.
†BP at screening will be measured at 0 minutes, 30 minutes, 1 hour and 2 hours after first test dose of bisoprolol.
‡Spirometry at screening will be measured at 0 minutes, 1 hour and 2 hours after first test dose of bisoprolol.
§Screening ECG will be 12-lead, all other measurements will be 3-lead.
¶CAT; SGRQ; EQ-5D-5L questionnaires.
** 6MWT (6 Minute Walk Test) is for a subset of the study population.
†† Clinic visits will involve pill counts. At phone visits, participants will be asked how many doses they missed.
CAT, COPD Assessment Test; ECG, Electrocardiogram; EQ-5D-5L, EuroQoL Group 5-Dimension self-report questionnaire; 6MWT, 6-minute walk test; SGRQ, St. George Respiratory Questionnaire.